Patient-reported most bothersome symptoms in OAB: Post hoc analysis of data from a large, open-label trial of solifenacin

International Urogynecology Journal

Volumn 20, Issue 6, 2009, Pages 667-675

  Sand, Peter K ^a   Steers, William D ^b   Dmochowski, Roger ^c   Andoh, Masakazu ^d   Forero Schwanhaeuser, Sergio ^e  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Most bothersome symptom; Overactive bladder; Patient reported outcomes; Solifenacin

Indexed keywords

SOLIFENACIN;

ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFESTATION; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NOCTURIA; OPEN STUDY; OVERACTIVE BLADDER; PERCEPTION; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; SYMPTOM; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; VISUAL ANALOG SCALE; XEROSTOMIA;

EID: 65749095895     PISSN: 09373462     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00192-009-0840-y     Document Type: Article

References (29)

1. Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 61:37-49
2. Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 50:1306-1314 discussion 1314-1305
3. Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327-336
4. Sand PK (2004) Elevating our therapeutic expectations in overactive bladder. J Am Acad Nurse Pract 16:8-11
5. Staskin DR, MacDiarmid SA (2006) Using anticholinergics to treat overactive bladder: The issue of treatment tolerability. Am J Med 119:9-15
6. Epstein BJ, Gums JG, Molina E (2006) Newer agents for the management of overactive bladder. Am Fam Physician 74:2061-2068
7. Haab F, Castro-Diaz D (2005) Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 59:931-937
8. Chapple CR, Martinez-Garcia R, Selvaggi L et al (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur Urol 48:464-470
9. Coyne KS, Matza LS, Kopp Z, Abrams P (2006) The validation of the patient perception of bladder condition (PPBC): A single-item global measure for patients with overactive bladder. Eur Urol 49:1079-1086
10. Abrams P, Artibani W, Gajewski JB, Hussain I (2006) Assessment of treatment outcomes in patients with overactive bladder: Importance of objective and subjective measures. Urology 68:17-28
11. Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R (2006) Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: The IMPACT trial. Int J Clin Pract 60:745-751
12. Roberts R, Bavendam T, Glasser DB, Carlsson M, Eyland N, Elinoff V (2006) Tolterodine extended release improves patient-reported outcomes in overactive bladder: Results from the IMPACT trial. Int J Clin Pract 60:752-758
13. Coyne KS, Elinoff V, Gordon DA et al (2008) Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Int J Clin Pract 62:925-931
14. Garely AD, Kaufman JM, Sand PK, Smith N, Masakazu A (2006) Symptom bother and health-related quality of life outcomes following Solifenacin treatment for overactive bladder: The VESIcare open-label trial (VOLT). Clin Ther 28:1935-1946
15. Leung HY, Yip SK, Cheon C et al (2002) A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. BJU Int 90:375-380
16. Davila GW, Daugherty CA, Sanders SW (2001) A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 166:140-145
17. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW (2003) Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62:237-242
18. Stach-Lempinen B, Kujansuu E, Laippala P, Metsänoja R (2001) Visual analogue scale, urinary incontinence severity score and 15 D-psychometric testing of three different health-related quality-of-life instruments for urinary incontinent women. Scand J Urol Nephrol 35:476-483
19. Lukacz ES, Lawrence JM, Burchette RJ, Luber KM, Nager CW, Buckwalter JG (2004) The use of Visual Analog Scale in urogynecologic research: A psychometric evaluation. Am J Obstet Gynecol 191:165-170
20. Coyne K, Revicki D, Hunt T et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Qual Life Res 11:563-574
21. Coyne KS, Matza LS, Thompson CL (2005) The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 14:849-855
22. Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V (2006) Determining the importance of change in the overactive bladder questionnaire, discussion 632. J Urol 176:627-632 discussion 632
23. Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS (2005) Test-retest reliability of four questionnaires for patients with overactive bladder: The overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 24:215-225
24. Garely AD, Lucente V, Vapnek J, Smith N (2007) Solifenacin for overactive bladder with incontinence: Symptom bother and health-related quality of life outcomes. Ann Pharmacother 41:391-398
25. Cardozo L, Lisec M, Millard R et al (2004) Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172:1919-1924
26. Chapple CR, Araño P, Bosch JL, De Ridder D, Kramer AE, Ridder AM (2004) Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 93:71-77
27. Chapple CR, Rechberger T, Al-Shukri S et al (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93:303-310
28. Chapple CR, Cardozo L, Steers WD, Govier FE (2006) Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 60:959-966
29. Institute of Medicine (2001) Crossing the quality chasm: A new health system for the 21st century. National Academy of Sciences, Washington DC